BLA 103976 · Genentech
Xolair
Omalizumab · Anti-IgE
NovelLast checked: Nov 20, 2026Latest source record: Aug 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Jun 20, 2003
Approved uses
9
Original approval plus efficacy supplements
Registered trials
209
53 Phase 3, 20 recruiting
FAERS reports
87,094
46,180 serious, 2,485 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ANAPHYLAXIS Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, initiate XOLAIR therapy in a healthcare setting and closely observe patients for an appropriate period of time after XOLAIR administration. Health care providers administering XOLAIR should be prepared to manage anaphylaxis which can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should symptoms occur. Selection of patients for self-administration of XOLAIR should be based on criteria to mitigate risk from anaphylaxis [see...
What it is approved for
From the label in effect Aug 13, 2026.
XOLAIR is an anti-IgE antibody indicated for: Moderate to severe persistent asthma in adults and pediatric patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids ( 1.1 ) Chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids, as add-on maintenance treatment ( 1.2 ) IgE-mediated food allergy in adult and pediatric patients aged 1 year and older for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods. To be used in conjunction with food allergen avoidance ( 1.3 ) Chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment ( 1.4 ) Limitations of Use : Not indicated for acute bronchospasm or status asthmaticus. ( 1.1 , 5.3 ) Not indicated for the emergency treatment of allergic reactions, including anaphylaxis ( 1.3 ) Not indicated for other forms of urticaria. ( 1.4 ) 1.1 Asthma XOLAIR is indicated for adults and pediatric patients 6 years of age and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. Limitations of Use: XOLAIR is not indicated for the relief of acute bronchospasm or status asthmaticus. 1.2 Chronic Rhinosinusitis with Nasal Polyps XOLAIR is indicated for add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids....
Mechanism: Asthma, Chronic Rhinosinusitis with Nasal Polyps, and IgE-Mediated Food Allergy Omalizumab inhibits the binding of IgE to the high-affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and dendritic cells, resulting in FcεRI down-regulation on these cells. In allergic asthmatics, treatment with omalizumab inhibits IgE-mediated inflammation, as evidenced by reduced blood and tissue eosinophils and reduced inflammatory mediators, including IL-4, IL-5, and IL-13. Chronic Spontaneous Urticaria Omalizumab binds to IgE and lowers free IgE levels. Subsequently, IgE receptors (FcεRI)...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 16, 2024 Supplement 5245 · Efficacy · priority review LabelLetter
- Apr 9, 2021 Supplement 5238 · Efficacy LabelLetter
- Nov 30, 2020 Supplement 5235 · Efficacy LabelLetter
- Sep 28, 2018 Supplement 5231 · Efficacy · priority review LetterLabelReview
- Jul 6, 2016 Supplement 5225 · Efficacy Pediatric Medical ReviewPediatric Clinical Pharmacology ReviewPediatric Statistical Review
- Sep 26, 2014 Supplement 5161 · Efficacy LabelLetter
- Mar 21, 2014 Supplement 5211 · Efficacy ReviewLabelLetter
- Jan 4, 2010 Supplement 5166 · Efficacy Letter
- Jun 20, 2003 Original approval · Type 1 - New Molecular Entity NovelOther Important Information from FDAPediatric Medical ReviewPediatric Clinical Pharmacology Review
4 products under this application
- XOLAIR · OMALIZUMAB 150MG/VIAL · VIAL, · Prescription
- XOLAIR · OMALIZUMAB 300MG/2ML · SYRINGE, · Prescription
- XOLAIR · OMALIZUMAB 75MG/0.5ML · SYRINGE, · Prescription
- XOLAIR · OMALIZUMAB 150MG/ML · SYRINGE, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Omalizumab" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)Pivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT00401596 · 1,899 participants · Start Jul 2000
Drug: Xolair (omalizumab) · For: Asthma
- A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03580356 · 1,078 participants · Start Oct 20, 2018 · Primary completion Jun 22, 2021
Drug: Ligelizumab; Omalizumab · For: Chronic Spontaneous Urticaria
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 183 sites in all
- A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistaminesPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03580369 · 1,072 participants · Start Oct 17, 2018 · Primary completion Jul 16, 2021
Drug: Ligelizumab; Omalizumab · For: Chronic Spontaneous Urticaria
Sites: Gilbert, Arizona; Litchfield Park, Arizona; Scottsdale, Arizona · 161 sites in all
- A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)Pivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT00314574 · 850 participants · Start Dec 2005 · Primary completion Nov 2009
Drug: omalizumab (Xolair); placebo and 2 more · For: Asthma
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01922037 · 806 participants · Start Jun 19, 2013 · Primary completion Mar 31, 2016
Drug: Omalizumab · For: Asthma
Sites: Birmingham, Alabama; Huntsville, Alabama; Gilbert, Arizona · 145 sites in all
- Cross-sectional Study for Identification and Description of Severe Asthma PatientsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02293265 · 767 participants · Start Dec 2014 · Primary completion May 2015
Drug: Short Acting Beta Agonist (SABA) · For: Asthma
Sites: Little Rock, Arkansas; Fresno, California; Los Angeles, California · 74 sites in all
- To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous UrticariaPivotal-lookingCompleted
CelltrionIndustry
NCT04426890 · 634 participants · Start Dec 9, 2020 · Primary completion Oct 21, 2022
Drug: CT-P39; EU-approved Xolair · For: Chronic Spontaneous Urticaria
Sites: Warsaw, Poland
- Safety and Efficacy Study of Omalizumab to Treat Allergic AsthmaPivotal-lookingCompleted
Shanghai Zhangjiang Biotechnology Limited CompanyIndustry
NCT01976208 · 630 participants · Start Dec 2010 · Primary completion Dec 2015
Drug: Omalizumab; placebo · For: Allergic Asthma
Sites: Beijing, China; Changchun, China; Chengdu, China · 27 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- asthma12,359
- urticaria11,739
- no adverse event11,200
- off label use11,096
- dyspnoea10,547
- drug ineffective8,624
- cough7,188
- pruritus6,575
- fatigue6,263
- malaise5,790
- wheezing5,674
- headache5,574
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 506 |
| 2005 | 528 |
| 2006 | 455 |
| 2007 | 705 |
| 2008 | 564 |
| 2009 | 864 |
| 2010 | 993 |
| 2011 | 1,196 |
| 2012 | 1,937 |
| 2013 | 1,613 |
| 2014 | 1,912 |
| 2015 | 2,180 |
| 2016 | 3,762 |
| 2017 | 7,651 |
| 2018 | 4,876 |
| 2019 | 5,460 |
| 2020 | 5,473 |
| 2021 | 5,295 |
| 2022 | 5,312 |
| 2023 | 5,719 |
| 2024 | 13,060 |
| 2025 | 9,846 |
| 2026 | 7,187 |
Recalls
3 FDA enforcement reports for this application.
Jul 30, 2025 · Class II · Ongoing
CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.
Jul 30, 2025 · Class II · Ongoing
CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.
Jun 9, 2021 · Class II · Terminated
Failed Stability Specifications: Out of Specification results of Polysorbate 20 (PS20) content were detected at the 12 month testing time point.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xolair (Omalizumab)
2024 spending
$313M
Beneficiaries
11,011
95,356 claims
Per beneficiary
$28,437
$1,381.49 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $150,601,321 |
| 2021 | $161,212,650 |
| 2022 | $208,230,097 |
| 2023 | $254,056,609 |
| 2024 | $313,118,329 |
Part B: Xolair (Omalizumab) · HCPCS J2357
2024 spending
$415M
Beneficiaries
17,605
184,319 claims
Per beneficiary
$23,566
2024 ASP limit $38.22 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $399,808,937 |
| 2021 | $401,920,803 |
| 2022 | $419,951,872 |
| 2023 | $419,776,545 |
| 2024 | $414,887,260 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.
Cao P, Xu W, Zhang L · Front Immunol 2022 · Systematic Review
- Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.
Maurer M, Casale TB, Saini SS, et al. · J Allergy Clin Immunol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Omalizumab for the Treatment of Multiple Food Allergies.
Wood RA, Togias A, Sicherer SH, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.
De Corso E, Canonica GW, Heffler E, et al. · Lancet Respir Med 2025 · Clinical Trial, Phase IV, Comparative Study
- Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta-Analysis of Real-World Evidence.
Cai S, Xu S, Zhao Y, et al. · Allergy 2025 · Meta-Analysis, Systematic Review
- Omalizumab in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis.
Jin M, Douglass JA, Elborn JS, et al. · J Allergy Clin Immunol Pract 2023 · Meta-Analysis, Systematic Review
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.